The abstract is read at the publisher; the summary is JClub's.
An induced pluripotent stem cell line, SCVli192-A, was generated from a patient with immune checkpoint inhibitor-induced myocarditis after Pembrolizumab and concurrent type 1 diabetes.
- Why it matters: Immune checkpoint inhibitor-induced myocarditis has heterogeneous presentations and may involve genetic susceptibility, limiting mechanistic study across patient-specific contexts.
- What they did: The team reprogrammed patient cells into a human iPSC line and confirmed typical morphology, a normal female karyotype, pluripotency, trilineage differentiation, Sendai virus clearance, and no mycoplasma contamination.
- The result: This patient-derived iPSC line expands resources to investigate immune checkpoint inhibitor-induced myocarditis heterogeneity and underlying mechanisms in a disease-relevant genetic background.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.